John Heymach, MD, PhD

home / authors / john-heymach-md-phd

Articles

Changing Landscape of EGFR+ mNSCLC

Changing Landscape of EGFR+ mNSCLC

John Heymach, MD, PhD
May 21st 2020
Repeat Testing at Progression of EGFR+ NSCLC

Repeat Testing at Progression of EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Practical Implications of the RELAY Trial in EGFR+ NSCLC

Practical Implications of the RELAY Trial in EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Treatment Options for EGFR+ NSCLC

Treatment Options for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
Molecular Testing for Newly Diagnosed NSCLC

Molecular Testing for Newly Diagnosed NSCLC

John Heymach, MD, PhD
May 21st 2020
Improved Outcomes for Patients With EGFR+ NSCLC

Improved Outcomes for Patients With EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
A 68-Year-Old Man With Metastatic EGFR+ NSCLC

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020
A 68-Year-Old Man With Metastatic EGFR+ NSCLC

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.

Characteristics of Additional KRAS Subsets in Lung Cancer

Characteristics of Additional KRAS Subsets in Lung Cancer

John Heymach, MD, PhD
May 13th 2015

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Innovative ctDNA Testing Drives Progress in NSCLC Research
Published: November 20th 2024 | Updated: November 22nd 2024
Innovative ctDNA Testing Drives Progress in NSCLC Research
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 22nd 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 22nd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 22nd 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 22nd 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer